montelukast

(redirected from Singulair)
Also found in: Medical.

mon·te·lu·kast

 (mŏn′tə-lo͞o′kăst)
n.
A drug that reduces the inflammatory response by acting as a leukotriene receptor antagonist, and is used to treat the signs and symptoms of asthma.

[monte-, of unknown origin + -lukast, leukotriene receptor antagonist suff.; see zafirlukast.]
Translations

montelukast

n montelukast m
References in periodicals archive ?
a subsidiary of Ajanta Pharma Limited, India, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg), generic versions of SINGULAIR Tablets and SINGULAIR Chewable Tablets, respectively.
Montelukast Sodium Tablets 10mg are therapeutically equal to Singulair Tablets 10mg of Merck Sharp & Dohme Corp.
A dip in sales caused by the Singulair patent expiry in 2012, as well as the patent expiry of numerous SABA, ICS, and ICS/LABA products over the forecast period, will be offset by eight pipeline product launches, seven of which are targeted biologics.
Add to that my child's allergy medicines, Singulair and Aerius, which each time we only got three-week's supply, but my child ended up doing that continually for about 10 years.
Butler is also optimistic about Merck's research and innovation capabilities, which will offset any revenue losses that may arise when its top-selling asthma and allergy pill, Singulair, expires in August.
Merck is cutting costs, expanding in emerging markets and spending on research and development as the company tries to gain momentum before it loses patent exclusivity next year on its Singulair medicine for asthma.
LTRAs, sold under the brand names Singulair and Accolate, have long been available as alternative treatments to ward off asthma attacks.
Whitehouse Station NJ) issued a more cautious 2010 profit outlook on Friday and reported disappointing second-quarter sales of its vaccines and Singulair asthma drug.
Since distribution of the "FDA Early Communication of an Ongoing Safely Review of Montelukas" on March 27, 2008, the FDA requested that Merck conduct additional evaluations of the data from clinical trials of SINGULAIR for reports of behavior and mood changes, and for reports of suicidality and suicide.
In chronic studies, Singulair produces improvements in objective (pulmonary function) and patient-reported events.
Extensive field-testing has proven that the Model 96 aerator costs less to operate and will outperform all previous Singulair aerator models and competitive units.
And because the Singulair granules contain a non-steroid drug, they can avoid large doses of potentially harmful steroids.